Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by hmmmmmmmmon Jan 06, 2023 11:13am
216 Views
Post# 35206886

RE:RE:RE:RE:RE:Any guesses

RE:RE:RE:RE:RE:Any guessesI would say it's a little too "neat" and conveniant for you to pretend like "pace" doesn't matter while you hope and preach about some "magical", early end to the trial. (year after year)
As an investor, I would much rather see management achieve real numbers and actual results. Straightforward stuff. But yes, that would require leaders who actually did their job and delivered on the "worst case" enrollment numbers they set for themselves. (I'll post a link to the AGM for clarity)


But I don't think "pace" is the only reason shareholders think as you say- "leaders suck" I think that's also because of:

-The Dialco mess and the complete disregard for real disclosure around it.
-Lack of transparency in general. (see Baxter deal, see Confirmed Partner #2", June Infomed contract issues...)
-Lack of credibility after 2 yrs of talking about starting DIMI trial and never getting close, or Seto's -reaching 90 patients by end of 2021 statements.
-Lack of accountability taken when they don't deliver.
-The pocket stuffing of millions of warrants- despite the lack of results.
-Financings that chop off 10%ish per year through dilution..

But you know all of these sucky reasons as you complain about them yourself from time to time.


https://spectraldx.com/wp-content/uploads/2022/09/spectral-investor-update-september-2022.pdf
<< Previous
Bullboard Posts
Next >>